, Volume 62, Issue 9, pp 1354–1354 | Cite as

Olmesartan Medoxomil

A Viewpoint by Gordon T. Mclnnes
  • Gordon T. McInnes
Adis New Drug Profile Guest Commentary


  1. 1.
    Oparil S, Chrysant SG, Marbury T, et al. CS-866 versus losartan, valsartan, and irbesartan in patients with essential hypertension. Am J Hypertens 2001; 14 (4 pt. 2): 180–1CrossRefGoogle Scholar
  2. 2.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345(12): 861–9PubMedCrossRefGoogle Scholar
  3. 3.
    Cohn J. Val-HeFT (Valsartan Heart Failure Trial). Clin Cardiol 2001 Jan; 24(1): 86Google Scholar
  4. 4.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 851–60PubMedCrossRefGoogle Scholar
  5. 5.
    Praving H-H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 870–8CrossRefGoogle Scholar
  6. 6.
    Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr 19; 87(8A): 33–6CrossRefGoogle Scholar
  7. 7.
    Mizuno M, Sada T, Ikeda M, et al. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats [abstract no. P-70]. Jpn J Pharmacol 1997; 73 Suppl. 1: 135Google Scholar
  8. 8.
    Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade on nitric oxide synthesis in rats. Circulation 2000 Jan; 101: 305–10PubMedCrossRefGoogle Scholar
  9. 9.
    Takemoto M, Egashira K, Tomita H, et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997 Dec; 30: 1621–7PubMedCrossRefGoogle Scholar
  10. 10.
    Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-\ via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998 Aug; 32: 273–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Gordon T. McInnes
    • 1
  1. 1.Department of Medicine and Therapeutics, Western InfirmaryUniversity of GlasgowGlasgowUK

Personalised recommendations